Verona Pharma’s Post

On November 7, 2023, Sage Therapeutics, the manufacturer of ZURZUVAE (zuranolone), announced that the wholesale acquisition cost of the postpartum depression drug would be $15,900 for a 14-day treatment cycle.💊💰 The drug, which was approved by the United States Food and Drug Administration (FDA) in August 2023, has effectively treated severe postpartum depression. #SageTherapeutics #Zuranolone #HealthcareInnovation #MedicalBreakthrough #TreatmentCosts #MedicalNews #HealthTech #InnovationInMedicine #SageAnnouncement #BiotechBuzz #HealthcareFinance #MedicalAdvancements #BioPharma #PatientCare #HealthcareForAll #rcm #medicalinsights #ushealthcare #cathodehealthcare

Is it hard to repurpose drugs?💊 Or is it fairly easy to get patient-centric, affordable medicines to the market these days❔❗ If you have any thoughts on this, you should definitely join our discussion at the 5th Value Added Medicines Conference on the 7th of November. We will look at the hardships and potential solutions of such drug development journeys together with Maja Graf, Laurent Martin, Pan Pantziarka, James Burt and Cesar Hernández García. #VAM23 #ValueAddedMeds

N0415: High-Risk Drug Classes was introduced with the launch of OASIS-E in January 2023. We have listed tips to help you accurately respond to N0415 in the OASIS. 

👁 Check out our interview with Atanas Koulov and John Shabushnig on future trends and challenges in #VisualInspection at the PDA - Parenteral Drug Association VI Forum in Munich last week! ❓ What are your challenges in visual inspection, comment below!

NY HCP's: do your patients use cannabis-based products? Lesson 4 of this series from @The_Answer_Page focuses on cannabinoid-based drug metabolism and potential drug interactions with prescribed medications. Pharmacy Podcast Network #NYCannabis Learn more: https://loom.ly/WmiG2aQ 

  Today is #WorldLungDay, an important moment each year to recognize the effects of #lungdisease and promote better #lunghealth for all.     This year, it comes at a crucial time for our team following the recent FDA acceptance of our NDA filing for #ensifentrine, our investigational drug for #COPD.     Ensifentrine's novel approach has the potential to have a major impact on the treatment of COPD. If approved on the PDUFA target action date, June 26, 2024, this treatment is expected to be the first new mechanism of action for the maintenance treatment of COPD in over a decade.     Learn more here: https://bit.ly/3r9WZDT  

After a multi-year lull, NASH R&D has picked up this past year with key data readouts, several programs advancing toward Phase III and Madrigal's resmetirom under FDA review with a March 2024 action. This graphic provides a look at the overall status of NASH drug R&D. https://lnkd.in/e5D3AHR7

3 weeks until ToxTime! ⏰ Gabapentin prescriptions have increased markedly as opioid prescriptions have been reduced, now making gabapentin the seventh most commonly prescribed drug in the US. That increase, though, is not without risk. In this complimentary ToxTime presentation, join Guida Brown, Principal of Guided By Guida, for a summary of the drug gabapentin, along with how it is being misused. Register now: https://zurl.co/OG7r

During a recent webinar we cohosted with the @Medical Review Institute of America, we discussed proven strategies for achieving a remarkable 15:1 ROI through their effective High-Cost Specialty Drug Reviews™ program. Whether you're new to managing high-cost specialty drugs or looking to enhance your existing processes, these insights are sure to empower you to make informed decisions. Reach out to sales@urmedwatch.com with any lingering questions, or watch the full webinar here if you missed it: https://lnkd.in/gm7aCfnM #SpecialtyDrugs #PopulationHealth #HealthcareSavings

#HospitalExecutives - What do you know about the 340B drug pricing program? CompleteRx has you covered with our in-depth Guide to Understanding the #340B Drug Pricing Program. Dive in and learn how you can optimize your drug pricing strategy and improve patient care. Click the link below to access the full guide! #340B #drugpricing #pharmacymanagement Link to full guide: https://lnkd.in/gc3FyTXy